Is the duration of adjuvant trastuzumab debate still clinically relevant?

[摘要]

[发布日期] [发布机构]

[效力级别] [学科分类]

[关键词] HER2-POSITIVE BREAST-CANCER;PLUS TRASTUZUMAB;OPEN-LABEL;CHEMOTHERAPY;MULTICENTER;COMBINATION;PERTUZUMAB;SAFETY;WOMEN [时效性]

浏览次数：3